Anti Cancer

Podcast: How Imagion is bringing cancer diagnostics into the 21st century

Finfeed Archived Aug 28, 2019

Imagion Biosystems (ASX:IBX) CEO, Robert Proulx speaks to Finfeed's Jonathan Jackson about the company's important work in early stage cancer detection.

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

Next Investors Archived Aug 14, 2019

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

Australia’s top biotechs descend on Queenstown for the 2019 Bioshares Summit

Finfeed Archived Jul 25, 2019

Queenstown, the New Zealand extreme sport mecca, hosts the annual Bioshares Biotech Summit, gathering together some of the best long-standing and emerging biotech companies in the country to talk all things trials, tribulations and potential cures for cancer.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Next Investors Archived Jul 25, 2019

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

Invion: Making a dynamic play in cancer treatment

Finfeed Archived May 23, 2019

Drug delivery company Invion Limited (ASX:IVX) is leading the way in developing PhotosoftTM technology for the treatment of a range of cancers.

GTG Validates Cancer Tests As it Looks to Global Expansion

Next Investors Archived May 14, 2019

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

Genetic Technologies shares rocket after cancer tests validated

Finfeed Archived May 13, 2019

Shares in Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) surged nearly 60% on Friday after the company announced two new ground-breaking cancer risk assessment tests had been completed and validated.

Genetic Technologies benefits from Healthy China Policy

Finfeed Archived Mar 28, 2019

Genetic Technologies (ASX:GTG), a provider of world-leading genetic risk assessment test products,has announced the establishment of its Asian operations within the Hainan Resort Software Community (HRSC) Free Trade Zone.

Imugene gains guidance for KEY-Vaxx Immunotherapy development

Finfeed Archived Mar 21, 2019

Imugene Limited (ASX:IMU) has now received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy.

First patient dosed in phase 2 trial with Imugene’s gastric cancer vaccine

Finfeed Archived Mar 14, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced dosing of the first patient in a in 68 patient randomised Phase 2 HER-Vaxx cancer trial.

Imugene to present cancer vaccine programs to the American Association for Cancer Research

Finfeed Archived Mar 04, 2019

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on its KEYVaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Cashed up Imugene to present at American Association for Cancer Research

Finfeed Archived Feb 28, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Next Investors Archived Jan 31, 2019

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

< prev Page 2 of 6 next >